Beth Israel Deaconess Medical Center: Researchers Compare Immune Responses Elicited by Three COVID-19 Vaccines
October 16, 2021
October 16, 2021
BOSTON, Massachusetts, Oct. 16 (TNSJou) -- Beth Israel Deaconess Medical Center issued the following news release:
Based on the strength of clinical trial data showing the vaccines conferred robust protection against COVID-19, the U.S. Food & Drug Administration granted emergency use authorization to the mRNA-based vaccines known as BNT162b2 (BioNTech, Pfizer) and mRNA-1273 (Moderna) in December 2020, and to the Ad26.COV2.S (Johnson & Johnson) single-shot vaccine in February . . .
Based on the strength of clinical trial data showing the vaccines conferred robust protection against COVID-19, the U.S. Food & Drug Administration granted emergency use authorization to the mRNA-based vaccines known as BNT162b2 (BioNTech, Pfizer) and mRNA-1273 (Moderna) in December 2020, and to the Ad26.COV2.S (Johnson & Johnson) single-shot vaccine in February . . .